Researchers from Tulane University and Shenzhen Third People's Hospital have developed ActCRISPR-TB, a CRISPR-Cas12a-based tuberculosis diagnostic test optimized for non-sputum samples such as cheek swabs and stool. The test improves sensitivity and returns results in under an hour, supporting rapid, affordable TB screening in low-income and rural areas. This one-pot reaction integrates amplification and detection, making it user-friendly for community applications.